Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5J3BL
|
|||
| Drug Name |
Bintrafusp alfa
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 2 | [1] | |
| Company |
EMD Serono; GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [2] |
| Transforming growth factor beta (TGFB) | Target Info | . | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.